###begin article-title 0
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
###end article-title 0
###begin p 1
Conceived and designed the experiments: PD MC LG MH AL MA CA OH. Performed the experiments: PD SL MC LG MH NC LB BH AL WS EV MA CA. Analyzed the data: PD MC LG MH NC BH AL WS MA CA PL CM AM OH. Wrote the paper: PD LG PL CM AM OH.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 144 152 144 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 157 164 157 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
The stem cell factor receptor, KIT, is a target for the treatment of cancer, mastocytosis, and inflammatory diseases. Here, we characterise the in vitro and in vivo profiles of masitinib (AB1010), a novel phenylaminothiazole-type tyrosine kinase inhibitor that targets KIT.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 168 170 168 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 282 284 280 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1223 1230 1219 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 326 331 <span type="species:ncbi:9606">human</span>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
###xml 1147 1152 <span type="species:ncbi:9606">human</span>
###xml 1157 1163 <span type="species:ncbi:10090">murine</span>
###xml 1267 1271 <span type="species:ncbi:10090">mice</span>
In vitro, masitinib had greater activity and selectivity against KIT than imatinib, inhibiting recombinant human wild-type KIT with an half inhibitory concentration (IC50) of 200+/-40 nM and blocking stem cell factor-induced proliferation and KIT tyrosine phosphorylation with an IC50 of 150+/-80 nM in Ba/F3 cells expressing human or mouse wild-type KIT. Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3. In contrast, masitinib demonstrated weak inhibition of ABL and c-Fms and was inactive against a variety of other tyrosine and serine/threonine kinases. This highly selective nature of masitinib suggests that it will exhibit a better safety profile than other tyrosine kinase inhibitors; indeed, masitinib-induced cardiotoxicity or genotoxicity has not been observed in animal studies. Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib. Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain. In vivo, masitinib blocked tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing a juxtamembrane KIT mutant.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 112 119 112 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 153 156 153 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Roskoski1">[1]</xref>
###xml 533 536 533 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Roskoski1">[1]</xref>
###xml 538 541 538 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Broudy1">[2]</xref>
###xml 704 707 704 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Reber1">[3]</xref>
###xml 998 1001 998 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Tests1">[4]</xref>
###xml 1003 1006 1003 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Lennarttson1">[5]</xref>
###xml 1160 1163 1160 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Orfao1">[6]</xref>
###xml 1286 1289 1286 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Roskoski1">[1]</xref>
###xml 1291 1294 1291 1294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Orfao1">[6]</xref>
The stem cell factor (SCF) receptor, KIT, also called CD117 or c-KIT receptor, is a member of the type III receptor protein-tyrosine kinase family (RTK) [1]. This family also includes Flt3, the platelet-derived growth factor (PDGF) receptor, and the receptor for macrophage colony-stimulating factor/colony-stimulating factor-1 (c-Fms). SCF and KIT regulate erythropoiesis, lymphopoiesis, megakaryopoiesis, gametogenesis, melanogenesis, with SCF also serving as an important growth factor and activator of mast cells and eosinophils [1], [2]. It is known that SCF is up-regulated in inflammatory conditions and therefore presents a potential therapeutic target for the treatment of inflammatory diseases [3]. In addition, gain-of-function mutations in KIT, that is mutations that cause constitutive activation of the tyrosine kinase (TK), have been implicated in a variety of neoplasms including, gastrointestinal stromal tumours (GIST), mastocytosis, acute leukaemias, melanomas and other cancers [4], [5]. These mutations are concentrated in the fifth extracellular domain (exons 8 and 9), the juxtamembrane region (exon 11), and the kinase domain (exon 17) [6]. Also, autocrine or paracrine activation of KIT is thought to be involved in ovarian neoplasms and small-cell lung cancer [1], [6].
###end p 9
###begin p 10
###xml 233 236 233 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Arora1">[7]</xref>
###xml 303 306 303 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Buchdunger1">[8]</xref>
###xml 368 371 368 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Buchdunger2">[9]</xref>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Dewar1">[10]</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Atwell1">[11]</xref>
###xml 695 699 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Rubin1">[12]</xref>
###xml 731 734 731 734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">816</sup>
###xml 793 796 793 796 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Orfao1">[6]</xref>
###xml 798 802 798 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Ma1">[13]</xref>
###xml 804 808 804 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Ueda1">[14]</xref>
###xml 877 881 877 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Kerkela1">[15]</xref>
###xml 883 887 883 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Fernandez1">[16]</xref>
###xml 1212 1220 1212 1220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1225 1232 1225 1232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 478 486 <span type="species:ncbi:9606">patients</span>
###xml 650 658 <span type="species:ncbi:9606">patients</span>
In the last decade, several inhibitors of TK have been developed for the treatment of cancer and other diseases. Imatinib mesylate (Gleevec, STI-571; Novartis, Basel, Switzerland) was the first TK inhibitor approved for clinical use [7]. This compound is a potent inhibitor of the PDGF receptor (PDGFR) [8] and also BCR-ABL, which causes chronic myelogenous leukaemia [9]. In addition, imatinib inhibits KIT, c-Fms and Syk [10], [11], and has been approved for the treatment of patients with KIT-positive nonresectable and/or malignant GIST. However, imatinib has a number of short-comings, including the development of resistance by most if not all patients with subsequent disease progression [12], as well as resistance of the D816V mutant, which is frequently associated with mastocytosis [6], [13], [14]. Moreover, imatinib may be cardiotoxic due to its inhibition of ABL [15], [16]. Therefore, novel TK inhibitors with improved selectivity are being developed for the treatment of diseases associated with KIT activation. Masitinib (AB1010), a protein TK developed by AB Science, S.A. (France), is one such new drug. The objective of this preclinical study was to provide a primary characterisation of the in vitro and in vivo activity of masitinib (mesylate salt) and to compare it against the benchmark protein TK inhibitor imatinib.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 41 46 <span type="species:ncbi:9606">human</span>
Masitinib is an inhibitor of recombinant human KIT
###end title 12
###begin p 13
###xml 65 74 65 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g001">Figure 1A</xref>
###xml 273 274 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 404 406 398 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 424 431 416 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 436 445 428 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g001">Figure 1B</xref>
###xml 689 698 675 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g001">Figure 1C</xref>
###xml 778 780 764 766 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 826 834 810 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007258.s002">Table S1</xref>
###xml 890 899 874 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g001">Figure 1D</xref>
###xml 109 114 <span type="species:ncbi:9606">human</span>
Activity of the synthetic TK inhibitor masitinib (mesylate salt; Figure 1A) was assessed using a recombinant human wild-type KIT protein corresponding to the intracellular domain (amino acids 567-976). Using poly(Glu,Tyr 4:1) as a substrate, the recombinant protein had a Km for ATP of 9.0+/-2.0 microM (data not shown). Masitinib inhibited the recombinant enzyme with a half inhibitory concentration (IC50) of 200+/-40 nM (Table 1 and Figure 1B). Kinetic studies in which ATP and masitinib were covaried showed that at concentrations </=500 nM masitinib is a competitive inhibitor against ATP, but at higher concentrations (>1 microM), it has a mixed mechanism of inhibition against ATP (Figure 1C). Under identical assay conditions and with the same enzyme, imatinib had an IC50 of 470+/-120 nM (see Supporting Information; Table S1) and was a strictly competitive inhibitor against ATP (Figure 1D).
###end p 13
###begin title 14
###xml 36 41 <span type="species:ncbi:9606">human</span>
Masitinib inhibition of recombinant human KIT.
###end title 14
###begin p 15
###xml 361 366 <span type="species:ncbi:9606">human</span>
(A) Structure of masitinib. The structure of masitinib is shown without its mesylate counterion. (B) Dose-response of masitinib at 10 microM ATP. Tyrosine phosphorylation by KIT was assayed by measuring the incorporation of phosphate into poly(Glu,Tyr 4:1). Lineweaver-Burk Plots for masitinib (C) and imatinib (D) with ATP as the varied substrate. Recombinant human KIT tyrosine kinase assays were performed using an ELISA-based assay with poly(Glu,Tyr 4:1) as a substrate. In (C), the lines intersect to the left of the Y-axis, indicating a mixed mechanism of inhibition for masitinib, whereas in (D), the lines intersect on the Y-axis, indicating a competitive mechanism of inhibition for imatinib.
###end p 15
###begin title 16
Effect of masitinib on the activity of protein kinases.
###end title 16
###begin p 17
###xml 144 149 <span type="species:ncbi:9606">human</span>
Recombinant tyrosine kinase assays were performed using an ELISA-based assay with poly(Glu,Tyr, 4:1) as the substrate. All protein kinases were human versions except where noted. Cell-based assays were performed using Ba/F3 cells expressing the various enzymes, and cell proliferation was assessed using WST-1. All concentrations were tested in duplicate (recombinant assays) or triplicate (cell-based assays). Results are the means+/-standard deviations from at least three independent experiments except where noted.
###end p 17
###begin p 18
Results are from a single experiment performed as part of a kinase screen by Proqinase (Germany).
###end p 18
###begin title 19
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 29 35 <span type="species:ncbi:10090">murine</span>
Masitinib inhibits human and murine KIT in intact cells
###end title 19
###begin p 20
###xml 174 178 174 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Kitayama1">[17]</xref>
###xml 532 534 532 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 552 559 550 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 564 573 562 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Figure 2A</xref>
###xml 595 597 593 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1107 1116 1101 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Figure 2B</xref>
###xml 1431 1440 1425 1434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Figure 2C</xref>
###xml 433 438 <span type="species:ncbi:9606">human</span>
###xml 1096 1101 <span type="species:ncbi:9606">human</span>
###xml 1380 1385 <span type="species:ncbi:9606">human</span>
Assessment of masitinib's and imatinib's ability to inhibit the function and activity of KIT in cells was conducted using the interleukin-3 (IL-3)-dependent cell line, Ba/F3 [17]. These cells normally cannot survive in the absence of IL-3, but they proliferate when transfected with transforming mutants of TKs or when transfected with wild-type receptor TKs and treated with the appropriate growth factor. In Ba/F3 cells expressing human wild-type KIT, masitinib dose-dependently inhibited SCF-induced cell proliferation with an IC50 of 150+/-80 nM, (Table 1 and Figure 2A). In contrast, the IC50 for inhibition of IL-3-stimulated proliferation occurred at approximately >5 microM, with inhibition in this case due to the ability of high concentrations of masitinib to inhibit other TKs in the cells. Imatinib showed a similar inhibitory pattern in this proliferation assay. Fluorescence-activated cell sorting (FACS) analysis of Annexin V/7-amino-actinomycin D-stained cells revealed that masitinib causes a dose-dependent induction of apoptosis in SCF-treated Ba/F3 cells expressing wild-type human KIT (Figure 2B). In contrast, masitinib-treated cells were rescued from apoptosis when treated with IL-3. Qualitative analyses by immunoprecipitation-western blotting experiments revealed that masitinib caused a parallel inhibition of SCF-stimulated tyrosine phosphorylation of human KIT, which was again observed with imatinib (Figure 2C). Inhibition of the KIT receptor was also associated with a parallel inhibition of KIT-secondary messengers such as AKT and ERK activation, with comparable dose effects observed between masitinib and imatinib treatment.
###end p 20
###begin title 21
Masitinib inhibition of KIT in intact cells.
###end title 21
###begin p 22
###xml 122 127 <span type="species:ncbi:9606">human</span>
###xml 249 255 <span type="species:ncbi:10090">murine</span>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 1113 1118 <span type="species:ncbi:9606">human</span>
###xml 1196 1202 <span type="species:ncbi:10090">murine</span>
###xml 2075 2081 <span type="species:ncbi:10090">murine</span>
(A) Effect of masitinib and imatinib on SCF and IL-3-stimulated cell proliferation. Ba/F3 cells expressing wild-type (WT) human (hKIT) were incubated for 48 hours with 0.1% conditioned medium from X63-IL-3 cells (IL-3) (filled symbols) or 250 ng/ml murine SCF in the presence of various concentrations of masitinib and imatinib. Cell proliferation was assessed by WST-1 colorimetric assay. (B) Induction of apoptosis by masitinib in Ba/F3 cells expressing wild-type human KIT. Cells were incubated for 24 hours with stem cell factor (SCF) or 0.1% conditioned medium from X63-IL-3 cells (IL-3) in the presence of various concentrations of masitinib. Apoptosis was assessed via Annexin V-phycoerythrin (PE) and 7-amino-actinomycin D (7-AAD) staining, followed by fluorescence-activated cell sorting. A second dataset was acquired for an incubation of 48 hours to verify completeness of the apoptosis process. (C) Effect of masitinib and imatinib on KIT tyrosine phosphorylation in Ba/F3 cells (upper panels) and phosphorylation of the downstream targets AKT and ERK (lower panels). Ba/F3 cells expressing wild-type human KIT (hKIT WT) were incubated for 5 minutes with (+) or without (-) 250 ng/ml murine SCF in the presence of various concentrations of masitinib and imatinib. Tyrosine phosphorylation of KIT, AKT and ERK, were assessed by immunoprecipitation (IP) with the relevant antibody, followed by western blotting (Blot) with anti-phosphotyrosine (pTyr) or anti-KIT molecular weight. Results are representative of at least three independent experiments. MW = molecular weight markers. (D) Comparison of masitinib's and imatinib's ability to inhibit the FcepsilonRI-mediated degranulation and cytokine production in cord blood derived mast cells (CBMC). Left: effect on the release of beta-hexosaminidase by IgE-anti IgE activated CBMC after 30 minutes of stimulation. Right: effect on cytokine production by IgE-anti IgE-activated CBMC after 4 hours of simulation via ELISA assessment of TNF-alpha release. (E) The effect of masitinib and imatinib on the migration of murine BMMCs in response to rmSCF stimulation.
###end p 22
###begin title 23
###xml 19 24 <span type="species:ncbi:9606">human</span>
Masitinib inhibits human mast cell degranulation, cytokine production and migration of bone marrow cells
###end title 23
###begin p 24
###xml 301 310 292 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Figure 2D</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
Assessment of masitinib's and imatinib's ability to inhibit the FcepsilonRI-mediated degranulation of human cord-blood-derived mast cells (CBMC) showed that both compounds produced a dose-dependent inhibition beta-hexosaminidase release by IgE-anti IgE activated CBMC after 30 minutes of stimulation (Figure 2D left). At concentrations of up to 10 microM, neither compound was able to completely block the release of this mediator; however, although not statistically different (p = 0.1), masitinib tended to be more potent than imatinib. At concentrations of 10, 1.0 and 0.1 microM, imatinib only slightly inhibited beta-hexosaminidase release by 19, 8 and 2%, respectively, compared to an inhibition of 35, 18 and 7%, respectively for masitinib. This effect was not due to cytotoxicity, as evident from the incubation of CBMC with masitinib for up to 9 hours having no affect on cell viability. Also, a possible confounding effect associated with the vehicle used to deliver masitinib or imatinib dimethyl sulphoxide (DMSO) can be excluded because the concentration used was below the threshold of effect.
###end p 24
###begin p 25
###xml 178 187 174 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Figure 2D</xref>
The effect of masitinib and imatinib on cytokine production of IgE-anti IgE-activated CBMC was explored via ELISA assessment of TNF-alpha release. As shown in the right panel of Figure 2D, masitinib and imatinib dose-dependently inhibited the release of TNF-alpha after 4 hours of stimulation. At concentrations of 10, 1.0 and 0.1 microM, masitinib inhibited TNF-alpha release by 68, 40 and 16%, respectively, whereas imatinib resulted in a weaker inhibition (p = 0.1) of 45, 24 and 4%, respectively. Hence, neither compound was able to completely block the release of this mediator, although both more potently inhibited TNF-alpha release than beta-hexosaminidase release.
###end p 25
###begin p 26
###xml 52 56 52 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Meininger1">[18]</xref>
###xml 227 236 227 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Figure 2E</xref>
###xml 110 116 <span type="species:ncbi:10090">murine</span>
###xml 183 188 <span type="species:ncbi:10090">mouse</span>
The KIT receptor is involved in mast cell migration [18]. We assessed the effect of masitinib and imatinib on murine bone marrow mast cell (BMMC) migration in response to recombinant mouse stem cell factor (rmSCF) stimulation (Figure 2E). After 4 hours of stimulation in the absence of either inhibitor, we observed a migration of BMMCs in response to SCF compared to unstimulated BMMCs (average migration of 8.7% versus 0.5% of the initial concentration, respectively). Upon treatment with 1.0 microM of masitinib, migration of SCF-stimulated BMMCs was inhibited approximately79.6% (p = 0.029) relative to the control. Imatinib similarly inhibited SCF-stimulated BMMC migration (58.1% relative to control), although this inhibition was significantly weaker than that of masitinib (p = 0.029).
###end p 26
###begin title 27
Masitinib inhibits KIT gain-of-function mutants
###end title 27
###begin p 28
###xml 102 105 102 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Orfao1">[6]</xref>
###xml 195 198 195 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">559</sup>
###xml 259 261 259 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 279 288 277 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g003">Figure 3A</xref>
###xml 293 300 291 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 395 404 393 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g003">Figure 3B</xref>
###xml 601 605 595 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Casteran1">[19]</xref>
###xml 705 707 695 697 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 725 732 713 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 737 746 725 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g003">Figure 3C</xref>
###xml 825 834 813 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g003">Figure 3D</xref>
###xml 931 934 919 922 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">816</sup>
###xml 1072 1074 1060 1062 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1096 1105 1078 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g003">Figure 3A</xref>
###xml 1110 1117 1092 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 1218 1221 1200 1203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">816</sup>
###xml 1233 1240 1215 1222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 1269 1272 1251 1254 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">814</sup>
###xml 1311 1313 1293 1295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1335 1344 1311 1320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g003">Figure 3C</xref>
###xml 1349 1356 1325 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 422 427 <span type="species:ncbi:10090">mouse</span>
###xml 1177 1182 <span type="species:ncbi:9606">human</span>
###xml 1250 1256 <span type="species:ncbi:10090">murine</span>
Gain-of-function mutations in KIT are associated with mastocytosis, GIST, and various human neoplasms [6]. In Ba/F3 cells, masitinib dose-dependently inhibited cell proliferation induced by the V559D mutant, commonly associated with GIST (exon 11), with an IC50 of 3.0+/-0.1 nM (Figure 3A and Table 1). Masitinib also caused a parallel inhibition of the tyrosine phosphorylation of this mutant (Figure 3B). In the Delta27 mouse mutant of KIT, which has a deletion of codons 547-555 in the juxtamembrane domain (exon 11) known to cause constitutive activation and ligand-independent cell proliferation [19], masitinib dose-dependently inhibited Delta27 KIT-dependent proliferation of Ba/F3 cells with an IC50 of 5.0+/-0.3 nM (Table 1 and Figure 3C). Masitinib also caused a parallel reduction in its tyrosine phosphorylation (Figure 3D). In contrast, masitinib only weakly inhibited the proliferation of Ba/F3 cells expressing the D816V mutant of KIT, which is associated with adult mastocytosis and myeloproliferative disorder-acute myeloid leukaemia (exon 17), with an IC50 of 5.0+/-2.0 microM (Figure 3A and Table 1). This result was corroborated by assays using recombinant human KIT intracellular domain with the D816V mutation (Table 1) and its murine equivalent D814V mutant, for which masitinib had an IC50 of 3.0+/-0.1 microM (Figure 3C and Table 1).
###end p 28
###begin title 29
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
Effect of masitinib on human and mouse KIT mutants.
###end title 29
###begin p 30
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Fig. 2A</xref>
###xml 305 308 305 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">559</sup>
###xml 449 456 441 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g002">Fig. 2B</xref>
###xml 92 97 <span type="species:ncbi:9606">human</span>
###xml 118 124 <span type="species:ncbi:10090">murine</span>
###xml 298 303 <span type="species:ncbi:9606">human</span>
###xml 343 349 <span type="species:ncbi:10090">murine</span>
Effect of masitinib on the proliferation of Ba/F3 cells expressing wild-type (WT) or mutant human (hKIT) (Fig. 3A) or murine (Fig. 3C) KIT (mKIT). Assessment of proliferation was as described for Fig. 2A. Effect of masitinib on tyrosine phosphorylation of KIT mutants in Ba/F3 cells expressing the human V559D mutant (hKIT V559D) (Fig. 3B) or murine Delta27 mutant (mKIT Delta27) (Fig. 3D). KIT tyrosine phosphorylation was assessed as described in Fig. 2B. IP = immunoprecipitation; Blot = western blot; MW = molecular weight markers.
###end p 30
###begin p 31
###xml 187 191 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Tsujimura1">[20]</xref>
###xml 199 201 195 197 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 269 278 261 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g004">Figure 4A</xref>
###xml 409 418 397 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g004">Figure 4B</xref>
###xml 575 584 563 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g004">Figure 4C</xref>
###xml 623 632 611 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g004">Figure 4D</xref>
###xml 644 646 632 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 677 679 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 745 754 727 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g004">Figure 4C</xref>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
To confirm the results in Ba/F3 cells, masitinib was tested in various mastocytoma cell lines. In HMC-1alpha155 and FMA3 cells, which carry KIT with mutations in the juxtamembrane domain [20], the IC50 values were approximately 10+/-1 nM and 30+/-1.5 nM, respectively (Figure 4A). Immunoprecipitation-western blotting experiments on HMC-1alpha155 revealed parallel reductions in KIT tyrosine phosphorylation (Figure 4B). Finally, the effect of masitinib on primary BMMCs from mice expressing wild-type KIT was examined. Masitinib inhibited SCF-stimulated cell proliferation (Figure 4C) and tyrosine phosphorylation of KIT (Figure 4D) with an IC50 of 200+/-50 nM, whereas the IC50 for IL-3-stimulated proliferation in these cells was >10 microM (Figure 4C).
###end p 31
###begin title 32
Effect of masitinib on cell proliferation and KIT tyrosine phosphorylation in mastocytoma cell-lines and BMMC.
###end title 32
###begin p 33
###xml 48 53 <span type="species:ncbi:9606">human</span>
###xml 97 103 <span type="species:ncbi:10090">murine</span>
(A) Effect of masitinib on the proliferation of human (HMC1, HMC-1alpha155) (filled symbols) and murine (P815, FMA3) mastocytoma cell lines harboring KIT mutants. Cells were incubated for 2 days with the indicated concentrations of masitinib. (B) western blotting analysis of HMC-1alpha155 tyrosine phosphorylation. (C) Effect of masitinib in the proliferation of BMMCs. BMMCs were incubated for 2 days with 250 ng/ml of stem cell factor (SCF) or 0.1% conditioned medium from X63-IL-3 cells (IL-3) with the indicated concentrations of masitinib. (D) Western blotting analysis of BMMC tyrosine phosphorylation. Cell proliferation was assessed by WST-1 colorimetric assay. Tyrosine phosphorylation of the KIT protein from sensitive cell types in (A) and (C) was analysed by immunoprecipitation (IP) and examined by western blotting (Blot) with antibodies to phosphotyrosine (anti-pTyr) or KIT (anti-Kit). MW = molecular weight.
###end p 33
###begin title 34
Selectivity of masitinib
###end title 34
###begin p 35
###xml 125 128 125 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Buchdunger1">[8]</xref>
###xml 130 133 130 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Buchdunger2">[9]</xref>
###xml 135 139 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Ueda1">[14]</xref>
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Small1">[21]</xref>
###xml 241 250 241 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g005">Figure 5A</xref>
###xml 255 262 255 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 344 346 344 346 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 383 391 383 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007258.s002">Table S1</xref>
###xml 528 537 520 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g005">Figure 5B</xref>
###xml 549 551 541 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 691 693 681 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 782 790 770 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 846 848 827 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 942 944 919 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 963 970 938 945 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 1010 1018 985 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1086 1088 1054 1056 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1181 1189 1145 1153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007258.s002">Table S1</xref>
###xml 1369 1371 1329 1331 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1510 1512 1458 1460 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1530 1540 1476 1486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g005">Figures 5C</xref>
###xml 1792 1802 1730 1740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g005">Figures 5D</xref>
###xml 1827 1828 1765 1766 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
Many TK inhibitors targeting KIT additionally inhibit other members of the class III TK receptors, especially ABL and PDGFRs [8], [9], [14], [21]. A study of masitinib's inhibitory action on a selection of these TKs was therefore conducted (Figure 5A and Table 1), along with a parallel examination of imatinib for direct comparison of their IC50 values (see Supporting Information; Table S1). In Ba/F3 cells expressing PDGFR-alpha, masitinib inhibited PDGF-BB-stimulated proliferation and PDGFR-alpha tyrosine phosphorylation (Figure 5B) with an IC50 of 300+/-5 nM. In contrast, masitinib showed relatively weak inhibition of cell proliferation in Ba/F3 cells expressing BCR-ABL, with an IC50 of 2800+/-800 nM. The corresponding recombinant assays show that masitinib inhibits the in vitro protein kinase activity of PDGFR-alpha and beta with IC50 values of 540+/-60 nM and 800+/-120 nM, respectively, and to a lesser extent ABL1, with an IC50 of 1200+/-300 nM (Table 1). Comparatively, imatinib inhibits the in vitro protein kinase activity of PDGFR-alpha, PDGFR-beta and ABL1 with IC50 values of 400 nM, 440+/-120 nM, and 270+/-130 nM, respectively (see Supporting Information; Table S1). Against other class III RTK, masitinib was inactive against Flt3 (>10 microM) but moderately inhibited c-Fms in both cell proliferation and recombinant protein kinase assays (IC50 of 1.0+/-0.03 microM and 1.48+/-0.54 microM, respectively). In addition, strong inhibition of proliferation was observed in EOL1 cells (IC50 of 0.2+/-0.1 nM; Figures 5C), a hypereosinophilic tumour cell line expressing the FIP1L1-PDGFRalpha chimeric protein, which is associated with chronic eosinophilic leukaemia. Similar inhibition was observed for tyrosine phosphorylation of the FIP1L1-PDGFRalpha chimeric protein (Figures 5D). This is a factor of 103 lower than that for the wild-type PDGFRalpha receptor.
###end p 35
###begin title 36
Effect of masitinib on BCR-ABL and PDGFRalpha.
###end title 36
###begin p 37
###xml 71 76 <span type="species:ncbi:9606">human</span>
###xml 111 116 <span type="species:ncbi:9606">human</span>
(A) Effect of masitinib on the proliferation of Ba/F3 cells expressing human wild-type KIT (hKIT WT), BCR-ABL, human wild-type PDGFRalpha (hPDGFRalpha WT). Cells were treated for 48 hours with PDGF-BB, IL-3, or SCF and in the presence of various concentrations of masitinib. Cell growth was assessed by WST-1 colorimetric assay. (B) Ba/F3 cells expressing hPDGFRalpha were treated for 5 minutes with PDGF-BB and various concentrations of masitinib. Tyrosine phosphorylation of PDGFRalpha was analysed by immunoprecipitation (IP), followed by western blotting (Blot) with an anti-phosphotyrosine (pTyr) antibody (upper panel) and an anti-PDGFRalpha antibody (lower panel). Results are representative of two independent experiments. (C) Effect of masitinib on the proliferation of EOL1 cells, a hyperoesinophilic tumour cell line expressing the FIP1L1-PDGFRalpha chimeric protein. (D) Western blotting analysis of EOL1 tyrosine phosphorylation. MW = molecular weight markers.
###end p 37
###begin p 38
###xml 401 408 401 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0007258-t001">Table 1</xref>
###xml 560 562 560 562 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
To extend the range of protein kinases tested against masitinib, various receptor TKs (VEGFR1 & 2; epidermal growth factor receptor; fibroblast growth factor receptor 1 & 2; insulin-like growth factor-I receptor; c-Met; TrkB; and c-Ret) and nonreceptor TKs (focal adhesion kinase; Lyn B; Src; Hck; Jak1; Jak2; Jak3; Tyk2; Btk; Bmx; and Syk) were examined using both recombinant and cell-based assays (Table 1). In general, masitinib was found to be either inactive or a weak inhibitor of all these TKs, with the exception of recombinant Lyn B, for which the IC50 was 510+/-130 nM. Finally, masitinib was inactive against three recombinant serine/threonine kinases (protein kinase C-alpha, Akt1, and Pim-1).
###end p 38
###begin title 39
Molecular modelling of masitinib binding to KIT and ABL
###end title 39
###begin p 40
###xml 156 164 156 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g006">Figure 6</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Nagar1">[22]</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Mol1">[23]</xref>
###xml 615 619 615 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">meta</italic>
###xml 692 701 692 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g006">Figure 6A</xref>
###xml 801 802 801 802 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1121 1130 1121 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g006">Figure 6C</xref>
###xml 1231 1248 1231 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g006">Figures 6B and 6D</xref>
###xml 1306 1315 1306 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g006">Figure 6D</xref>
###xml 1510 1519 1510 1519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g006">Figure 6B</xref>
###xml 264 269 <span type="species:ncbi:9606">human</span>
###xml 516 526 <span type="species:ncbi:111938">gatekeeper</span>
Molecular modelling studies were performed to help determine how masitinib binds selectively to KIT and to compare its mode of binding to that of imatinib (Figure 6). Masitinib was docked into the ATP-binding site of wild-type KIT and ABL using the coordinates of human KIT and ABL in the inactive conformation. Both kinases have been co-crystallised with imatinib (STI-571) [22], [23]. When docked into the KIT binding site, the aminothiazole of masitinib participates in a hydrogen bond with the side-chain of the gatekeeper residue Thr670. The amide NH forms a hydrogen bond to the side-chain of Glu640, and the meta-nitrogen of the pyridine ring interacts with the backbone NH of Cys673 (Figure 6A). For the methylpiperazine group, an additional hydrogen bond is observed between the protonated CH3-NH and the backbone-CO of His790. The thiazole ring of masitinib packs loosely between the aliphatic portions of the side-chains of Ala621, Leu799, Cys809, and Phe811. Binding of masitinib to ABL occurs in a similar manner, although small differences are observed near the DFG motif (Phe810 in KIT and Phe382 in ABL) (Figure 6C). There are close similarities between the modes of KIT and ABL binding for imatinib and masitinib (Figures 6B and 6D). Differences are apparent, however, in the ABL complex (Figure 6D), where the polar pyrimidine ring of imatinib is involved in a strong hydrogen bond network to three co-crystallised water molecules bound to the DFG motif. In the KIT-imatinib X-ray structure (Figure 6B), only one loosely bound water molecule is observed in the corresponding region indicating a more hydrophobic environment. This dissimilarity arises because the thiazole ring of masitinib is more hydrophobic than imatinib's pyrimidine ring and is unable to mediate a hydrogen bond to the water molecules. Consequently, preferred binding of masitinib by KIT is observed.
###end p 40
###begin title 41
###xml 24 29 <span type="species:ncbi:9606">human</span>
Docking of masitinib to human KIT and ABL: comparison with imatinib binding.
###end title 41
###begin p 42
(A and B) details of the binding of masitinib (A; green; docking pose) and imatinib (B; orange; X-ray structure 1T46.pdb) to the KIT kinase domain. Masitinib and imatinib interact with the protein via hydrogen bonds involving Glu640, Thr670, Cys673, and His790 and van der Waals interactions with Ala621, Val643, Leu644, Val668, Tyr672, Leu799, Cys809, and Phe811. Cys809 and Phe811, which form a hydrophobic groove for the thiazole and pyrimidine ring, respectively, are shown as space-filling structures. (C and D) Details of the binding of masitinib (C; green; docking pose) and imatinib (right site; orange; X-ray structure 1IEP.pdb) to the ABL kinase domain. Masitinib and imatinib interact with the protein via hydrogen bonds involving Glu286, Thr315, Phe317, and His361 and van der Waals interactions with Tyr252, Ala268, Val289, Met290, Ile313, Phe317, Leu370, and Phe382. In addition, the pyrimidine ring of imatinib is involved in a hydrogen bond network to conserved water molecules around the DFG motif of ABL (shown as red balls).
###end p 42
###begin title 43
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Masitinib inhibits tumour growth in vivo
###end title 43
###begin p 44
###xml 103 110 99 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 302 303 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 777 786 769 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g007">Figure 7A</xref>
###xml 1139 1148 1131 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g007">Figure 7B</xref>
###xml 2 7 <span type="species:ncbi:10090">mouse</span>
###xml 121 130 <span type="species:ncbi:10090">Nude mice</span>
###xml 349 353 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">mice</span>
###xml 1077 1081 <span type="species:ncbi:10090">mice</span>
A mouse model of tumour growth with Delta27-expressing Ba/F3 cells was used to investigate masitinib's in vivo activity. Nude mice were gamma-irradiated and implanted after 24 hours with Delta27-expressing Ba/F3 cells by subcutaneous injection. When the tumours had grown to an average volume of 400 mm3 (19 days post implantation of tumour cells), mice were treated with intraperitoneal injection of 30 mg/kg masitinib or placebo (i.e. vehicle control) (n = 10 per group) twice daily for 25 days and tumour volume was assessed every 5 days. At the start of treatment, the mean tumour volumes were not statistically different between groups (p = 0.617). Tumour growth stabilised in mice treated with masitinib, whereas placebo treated mice had a mean doubling time of 5 days, (Figure 7A). A significant difference in average tumour volume was evident after 10 days of treatment (day 29), the placebo group showing an approximate 4-fold increase compared to the masitinib treated group (p = 0.016). The administered dose of masitinib did not affect the total body weight of the mice during the course of the study. Furthermore, as shown in Figure 7B, masitinib increased the median survival time from 30.5 to 42 days (p<0.001) relative to the control population.
###end p 44
###begin title 45
###xml 33 40 33 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
Masitinib inhibits tumour growth in vivo.
###end title 45
###begin p 46
###xml 87 88 87 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 300 301 292 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 747 748 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 0 9 <span type="species:ncbi:10090">Nude mice</span>
###xml 116 122 <span type="species:ncbi:10090">murine</span>
###xml 329 333 <span type="species:ncbi:10090">Mice</span>
###xml 776 780 <span type="species:ncbi:10090">Mice</span>
Nude mice were gamma-irradiated and after 24 hours, injected subcutaneously with 1.5x106 Ba/F3 cells expressing the murine Delta27 KIT mutant. (A and B) Effect of intraperitoneal administered masitinib treatment on Delta27 KIT-expressing tumours, with an average pre-treatment tumour volume of 400 mm3 (large tumour experiment). Mice were treated with 30 mg/kg masitinib or a placebo (vehicle control) (n = 10 per group) twice daily for 25 days by intraperitoneal injection. (A) Mean tumour volume assessed every 5 days during the treatment. D19 corresponds to the first day of treatment. (B) Kaplan-Meier survival plot. (C) Effect of oral masitinib treatment on Delta27 KIT-expressing tumours, with an average pre-treatment tumour volume of 40 mm3 (small tumour experiment). Mice were treated twice daily for 11 days with masitinib administered orally at 0 (controls), 10, 30, or 45 mg/kg. D14 corresponds to first day of treatment.
###end p 46
###begin p 47
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 798 807 798 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g007">Figure 7C</xref>
###xml 1595 1596 1591 1592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">Mice</span>
###xml 1042 1046 <span type="species:ncbi:10090">mice</span>
###xml 1352 1356 <span type="species:ncbi:10090">mice</span>
###xml 1517 1521 <span type="species:ncbi:10090">mice</span>
To examine the effect of orally administered masitinib on small tumour volumes, mice with an average tumour volume of 40 mm3 (14 days post implantation of tumour cells) were assigned to one of five groups: masitinib at 10, 30, or 45 mg/kg; placebo (vehicle control); or untreated (n = 8 per group). At the start of treatment, the mean tumour volumes were not statistically different between groups (p = 0.236). Treatment was administered twice daily for 10 days with tumour size measured every 5 days during the treatment period. Mice treated with masitinib showed a dose-dependent inhibition of tumour growth, whereas the vehicle-treated population showed continuous tumour growth with an estimated doubling time of 1 day; corresponding to a tumour volume increase of 1200% between days 14 to 25 (Figure 7C). Masitinib at 30 or 45 mg/kg significantly reduced tumour growth following 11 days of treatment compared to placebo, with average tumour volume increases of 355% (p = 0.05) and 154% (p = 0.005), respectively in the masitinib-treated mice. However, the lower masitinib dose of 10 mg/kg did not substantially alter tumour size relative to control (p = 0.940). For one and two animals receiving masitinib at 30 and 45 mg/kg respectively, there were no detectable tumours at day 25. These doses of masitinib did not affect body weight gain of the mice during the course of the study. Finally, we performed a separate experiment to examine the effect of twice daily, orally administered masitinib at 100 mg/kg on mice having large Delta27 KIT-expressing tumours (average tumour volume 500 mm3, 26 days post implantation of tumour cells). We found that tumour growth was blocked following 5 days of treatment with masitinib (data not shown). Upon withdrawal of masitinib treatment after day 5, tumour growth was once again evident.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 73 80 73 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 268 270 268 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 340 342 340 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 427 435 423 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007258.s002">Table S1</xref>
###xml 610 612 606 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 813 815 797 799 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 822 824 806 808 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1131 1135 1115 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Small1">[21]</xref>
###xml 1137 1141 1121 1125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Wilhelm1">[24]</xref>
###xml 1143 1147 1127 1131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Mendel1">[25]</xref>
###xml 1383 1387 1367 1371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Small1">[21]</xref>
###xml 1389 1393 1373 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Shchemelinin1">[26]</xref>
###xml 1739 1743 1723 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Nagar1">[22]</xref>
In the current set of experiments we have characterised the in vitro and in vivo profiles of masitinib, a novel phenylaminothiazole-type TK inhibitor. Of the protein kinases tested, the most sensitive to masitinib were KIT and PDGFR, both of which had submicromolar IC50 values. In addition, masitinib was a good inhibitor of Lyn kinase (IC50 of 510+/-130 nM compared to 2200+/-100 nM for imatinib, see Supporting Information; Table S1), and to a lesser extent, fibroblast growth factor receptor 3. In contrast to many other KIT inhibitors, such as imatinib, masitinib is a relatively weak inhibitor of ABL (IC50 for recombinant KIT = 1.2+/-0.34 microM for masitinib versus0.27+/-0.13 microM for imatinib), and the relative selectivity for KIT versus ABL was 10-fold higher for masitinib than for imatinib (ABL IC50/KIT IC50 = 6.0 for masitinib versus 0.6 for imatanib). Masitinib was shown to be inactive against Flt3 and a relatively weak inhibitor of c-Fms, which are two members of the class III RTKs. Masitinib was also inactive against the vascular endothelial growth factor receptor, a RTK often inhibited by KIT inhibitors [21], [24], [25]. In contrast, other KIT inhibitors, including imatinib, dasatinib (Sprycel, Bristol-Myers Squibb), and sunitinib (Sutent, Pfizer), also inhibit several other protein kinases, especially other members of the type III receptor TK family [21], [26]. Thus, masitinib appears to be the most specific inhibitor of KIT. Our molecular modelling studies suggest that this greater selectivity of masitinib may be due to an inability to form hydrogen bonds to three water molecules in the active site of ABL, despite both compounds binding to the active sites of KIT and ABL with similar conformations [22].
###end p 49
###begin p 50
###xml 177 181 177 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Kerkela1">[15]</xref>
###xml 183 187 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Fernandez1">[16]</xref>
###xml 383 387 383 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Kerkela1">[15]</xref>
###xml 975 979 975 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Imatinib1">[27]</xref>
###xml 1064 1086 1064 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Salmonella typhimurium</italic>
###xml 1091 1107 1091 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
###xml 879 884 <span type="species:ncbi:9606">human</span>
###xml 1064 1086 <span type="species:ncbi:90371">Salmonella typhimurium</span>
###xml 1091 1107 <span type="species:ncbi:562">Escherichia coli</span>
###xml 1162 1167 <span type="species:ncbi:9606">human</span>
###xml 1261 1266 <span type="species:ncbi:10090">mouse</span>
###xml 1384 1389 <span type="species:ncbi:10090">mouse</span>
The lack of specificity associated with other KIT inhibitors may lead to toxic side effects and recent studies suggest that imatinib may be cardiotoxic due to inhibition of ABL [15], [16]. Indeed, the cardiotoxicity of imatinib was reported with observation of left ventricular dysfunction and even frank congestive heart failure in patients without a prior history of heart disease [15]. In contrast, the pharmacological profile of masitinib shows that it does not target the kinases presumably involved in cardiotoxicity, e.g. SRC, vascular endothelial growth factor receptors (VEGFR), endothelial growth factor receptors (EGFR) and Abelson proto-oncogene ABL. Thus, the risk of cardiotoxicity appears to be lower with masitinib than with imatinib. In addition to cardiotoxicity, imatinib has been shown to be genotoxic as indicated by a positive chromosome aberration test in human lymphocytes in Chinese Hamster Ovary (CHO) cells and in a bacterial reverse mutation test [27]. Masitinib, in contrast, is not mutagenic in bacterial reverse mutation tests using Salmonella typhimurium and Escherichia coli and does not cause chromosome aberrations in cultured human lymphocytes. Masitinib also does not cause damage to chromosomes or the mitotic apparatus in mouse bone marrow cells following two daily administrations at 437.5, 875, or 1750 mg/kg/day, and it is not mutagenic in a mouse lymphoma assay (our unpublished results).
###end p 50
###begin p 51
###xml 98 101 98 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">559</sup>
###xml 144 147 144 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Orfao1">[6]</xref>
###xml 444 447 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Orfao1">[6]</xref>
###xml 590 592 586 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 638 640 634 636 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 750 752 746 748 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 860 862 856 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1002 1006 998 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Zermati1">[28]</xref>
###xml 1008 1012 1004 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Frost1">[29]</xref>
###xml 155 161 <span type="species:ncbi:10090">murine</span>
###xml 807 813 <span type="species:ncbi:10090">murine</span>
Importantly, masitinib was a potent inhibitor of several gain-of-function KIT mutants, including V559D (exon 11), which is associated with GIST [6], and a murine KIT mutant with a deletion of nine amino acids in the juxtamembrane domain (Delta27 mutant; exon 11). This suggests that masitinib will be effective for the treatment of diseases linked to activating mutations in KIT, which includes mastocytosis, GIST, and canine mast cell tumours [6]. Furthermore, exon 11 mutants, which appear to be the most common type of KIT mutation in these diseases, were more sensitive to masitinib (IC50 = 3 to 20 nM) than the wild-type receptor (IC50 = 150 nM). In support of this, we found that mastocytoma cell lines carrying KIT juxtamembrane mutants had IC50 values for masitinib between 10 and 30 nM, whereas in murine primary BMMCs expressing wild-type KIT, the IC50 for masitinib was 200 nM. This higher sensitivity of juxtamembrane mutants than the wild-type receptor has also been reported for imatinib [28], [29].
###end p 51
###begin p 52
###xml 352 356 341 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Cools1">[30]</xref>
Masitinib was a potent inhibitor of mutant PDGFR alpha and beta receptors found in GIST and Chronic Myelomonocytic Leukaemia, respectively. Interestingly, masitinib is also very active against the protein FIP1L1-PDGFRalpha, which is generated from an internal deletion of chromosome 4 and is responsible for the induction of hypereosinophilic syndrome [30]. Masitinib therefore may be useful for the treatment of tumours involving mutant PDGF receptors.
###end p 52
###begin p 53
###xml 49 56 49 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 523 530 519 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 733 737 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Hahn1">[31]</xref>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 570 574 <span type="species:ncbi:9615">dogs</span>
Our studies also showed that masitinib is active in vivo. Intraperitoneal or oral administration of masitinib inhibited tumour growth in mice with subcutaneous grafts of Ba/F3 cells expressing the Delta27 KIT mutant. Furthermore, in an intraperitoneal model, masitinib significantly enhanced survival with no indication of general toxicity, as indicated by a lack of weight loss at the administered doses. These results demonstrate that masitinib is orally bioavailable and that it is effective at inhibiting tumour growth in vivo. This agrees with our phase 3 study in dogs showing that orally administered masitinib is safe and effective for the treatment of nonresectable or recurrent grade 2 or 3 nonmetastatic mast cell tumours [31].
###end p 53
###begin p 54
###xml 159 167 159 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
In conclusion, our results show that masitinib is a potent and selective inhibitor of the KIT TK. Moreover, it appears to have higher affinity and selectivity in vitro than other TK inhibitors and does not inhibit kinases that are linked to toxic effects. Masitinib also potently inhibits recombinant PDGFR, the intracellular kinase Lyn, and, to a lesser extent, FGFR3. Additionally, masitinib was active and orally bioavailable. Thus, we anticipate that masitinib will be effective for the treatment of KIT and PDGFR-dependent diseases, which include various cancer and inflammatory diseases, and that it will have a better safety profile, especially regarding cardiotoxicity, than other KIT inhibitors.
###end p 54
###begin title 55
Materials and Methods
###end title 55
###begin title 56
Drug product
###end title 56
###begin p 57
###xml 140 143 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Buchdunger1">[8]</xref>
###xml 145 148 145 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Buchdunger2">[9]</xref>
###xml 334 336 334 336 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 337 339 337 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">30</sub>
###xml 340 341 340 341 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sub>
###xml 346 347 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 348 349 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 352 361 352 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007258-g001">Figure 1A</xref>
Masitinib was identified using a medicinal chemical approach to improve the selectivity of the phenylaminopyrimidine class of TK inhibitors [8], [9]. The chemical name is 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3ylthiazol-2-ylamino) phenyl]benzamide-mesylate methane sulfonic acid salt, and the chemical formula is C28H30N6OS.CH4O3S (Figure 1A). Masitinib used in these studies was synthesised by either AB Science, S.A. (France), Archemis (Decines Charpieu, (France), Syngene (Bangalore, India) or by Prestwick Chemical, Inc. (France); for detailed procedure refer to patent WO/2008/098949. Its chemical structure was confirmed by nuclear magnetic resonance, mass spectrometry, ultraviolet and infrared spectrometry, and elemental analysis. Masitinib is practically insoluble in 0.1 M NaOH and n-hexane, slightly soluble in ethanol and propylene glycol, soluble in water, and freely soluble in 0.1 M HCl and dimethylsulfoxide. The compound, a white powder, was dissolved as a 10 or 20 mM stock solution in dimethylsulfoxide and stored at -80degreesC. Fresh dilutions of masitinib were made for each experiment. The imatinib used in this study was purchased from Sequoia Research (UK).
###end p 57
###begin title 58
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro assays with recombinant protein kinases
###end title 58
###begin p 59
###xml 367 377 364 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007258.s001">Methods S1</xref>
###xml 709 719 702 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007258.s001">Methods S1</xref>
###xml 47 52 <span type="species:ncbi:9606">human</span>
Full details for the generation of recombinant human KIT intracellular domain and other protein kinases (including Lyn, platelet derived growth factor receptor beta, epidermal growth factor receptor, fibroblast growth factor receptor 1, Src, HCK, PYK, FES, Btk, Bmx, c-Ret, c-Fms, Syk, and c-Met) are provided in the Supplemental Methods (see Supporting Information; Methods S1). Experiments on ABL1, Akt1, protein kinase C-alpha, insulin-like growth factor receptor 1, and Pim1 were carried out by Proqinase (Germany). All other recombinant protein kinases were performed in-house using an enzyme-linked immunoassay; experimental details are provided in the Supplemental Methods (see Supporting Information; Methods S1).
###end p 59
###begin title 60
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro assays in intact cells
###end title 60
###begin p 61
###xml 12 16 12 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Zermati1">[28]</xref>
###xml 18 22 18 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-GabillotCarre1">[32]</xref>
###xml 313 316 303 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">816</sup>
###xml 323 326 313 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">559</sup>
###xml 380 384 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Casteran1">[19]</xref>
###xml 386 390 376 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-GabillotCarre1">[32]</xref>
###xml 232 236 <span type="species:ncbi:9913">calf</span>
###xml 329 335 <span type="species:ncbi:10090">murine</span>
###xml 340 345 <span type="species:ncbi:9606">human</span>
###xml 466 471 <span type="species:ncbi:9606">human</span>
###xml 492 497 <span type="species:ncbi:10090">mouse</span>
###xml 565 571 <span type="species:ncbi:10090">murine</span>
###xml 590 593 <span type="species:ncbi:10116">rat</span>
Ba/F3 cells [28], [32] were grown at 37degreesC in Roswell Park Memorial Institute medium (RPMI) 10 (RPMI 1640 with L-glutamine, supplemented with 100 units/ml penicillin, 100 microg/ml streptomycin, and 10% heat-inactivated foetal calf serum). The generation of Ba/F3 cells expressing wild-type or mutant (e.g. D816V and V559D) murine and human KIT has been previously described [19], [32]. All cells were analysed and sorted by FACS for cell surface expression of human KIT using MAB332, a mouse anti-KIT monoclonal antibody (R&D Systems Europe, France), and for murine KIT using ACK2, a rat anti-KIT monoclonal antibody (Clinisciences SA, France). Cells expressing the constitutively activated mutant forms of KIT mutant were selected according to their ability to proliferate in the absence of IL-3.
###end p 61
###begin p 62
###xml 91 92 91 92 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 154 160 <span type="species:ncbi:9913">bovine</span>
###xml 284 290 <span type="species:ncbi:10090">murine</span>
###xml 300 306 <span type="species:ncbi:10090">murine</span>
For the assay of Ba/F3 cell proliferation, microtitre plates were seeded with a total of 104 cells/well in 100 microl of RPMI 1640 medium with 10% foetal bovine serum at 37degreesC. These were supplemented, or not, with either 0.1% conditioned medium from X63-IL-3 cells or 250 ng/ml murine SCF. The murine SCF, which activates KIT, was purified from the conditioned medium of SCF-producing CHO cells (gift of S. Lyman, Immunex). Cells were grown for 48 hours at 37degreesC and then incubated with 10 microl/well of WST-1 reagent (Roche Applied Science, France) for 3 hours at 37degreesC. The amount of formazan dye formed was quantified by its absorbance at 450 nm using a scanning multiwell spectrophotometer (MultiSkan MS, Thermo-LabSystems, France). A blank well without cells was used as a background control for the spectrophotometer and all assays were performed in triplicate.
###end p 62
###begin p 63
###xml 449 455 <span type="species:ncbi:9986">rabbit</span>
###xml 723 734 <span type="species:ncbi:3704">horseradish</span>
###xml 762 768 <span type="species:ncbi:9986">rabbit</span>
###xml 816 827 <span type="species:ncbi:3704">horseradish</span>
###xml 855 860 <span type="species:ncbi:10090">mouse</span>
Apoptotic and dead cells were detected using annexin V-phycoerythrin and 7-amino-actinomycin D via FACScan (Becton Dickinson, USA), according to the manufacturer's instructions (BD Biosciences Pharmingen, France). Full details for the analysis of tyrosine phosphorylation in intact cells are provided in the Supplemental Methods. Western blotting was performed using one of the following primary antibodies: for KIT, 1:1000 dilution of a polyclonal rabbit anti-KIT antibody (Cell Signalling Technology, France); for PDGFR-alpha 0.2 microg/ml anti-PDGFR-alpha antibody sc-338 (Ozyme, France); for phosphotyrosine, using 1:1000 anti-phosphotyrosine antibody 4G10 (Cell Signalling Technology). These were followed by 1:10,000 horseradish peroxidase-conjugated anti-rabbit antibody (Jackson Laboratory, USA) or 1:20,000 horseradish peroxidase-conjugated anti-mouse antibody (Dako-France SAS, France). Immunoreactive bands were detected using enhanced chemiluminescent reagents (Pierce, USA).
###end p 63
###begin p 64
###xml 277 282 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 282 286 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Royer1">[33]</xref>
###xml 316 326 312 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0007258.s001">Methods S1</xref>
###xml 783 787 765 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Razin1">[34]</xref>
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 583 587 <span type="species:ncbi:9925">goat</span>
###xml 593 598 <span type="species:ncbi:9606">human</span>
Assessment of the effect of masitinib and imatinib on human mast cell degranulation response and cytokine production (TNF-alpha release), was performed on CBMC produced by long-term culture of CD34+ progenitors purified from normal cord-blood, as described previously by Royer et al[33] (see Supporting Information; Methods S1). Cultured cells were harvested, washed in complete IMDM medium, and incubated for 1 hour in various concentrations of masitinib or imatinib. Assays of beta-hexosaminidase release and TNF-alpha release were made by stimulating the CBMC with 1 microg/ml of goat anti-human IgE (Vector Laboratories) for 30 minutes or 4 hours, respectively. beta-hexosaminidase was measured in the supernatant and in the sonicated cell pellets and its net release calculated [34]. For TNF-alpha determination, the cell-free supernatants were collected by centrifugation and frozen at -80degreesC until determination of mediator content by the use of a specific ELISA kit according to manufacturer's instructions (Coulter, France). All assays were performed in duplicate and counts were repeated twice for each well. Results were expressed in percentage of inhibition of beta-hexosaminidase release and of TNF-alpha release relative to the stimulated untreated CBMC, (i.e. 100% of stimulation).
###end p 64
###begin p 65
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Zou1">[35]</xref>
###xml 95 96 95 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 540 541 522 523 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 768 769 750 751 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 925 927 901 903 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 13 19 <span type="species:ncbi:10090">murine</span>
###xml 170 176 <span type="species:ncbi:9913">bovine</span>
###xml 866 870 <span type="species:ncbi:9913">calf</span>
Migration of murine BMMCs was evaluated using a transwell migration assay [35]. Briefly, 2.5x105 unstarved mast cells in 100 microL of chemotaxis buffer (RPMI 1640, 0.5% bovine serum albumin [BSA], 1% antibiotics) were loaded onto each transwell filter (8 microm pore, 24-well cell clusters; Becton Dickinson, USA). Filters were then placed in wells containing 600 microL of chemotaxis buffer supplemented with or without 10 ng/mL of rmSCF, for stimulated or unstimulated BMMCs, respectively. After 4 hours incubation at 37degreesC in 5% CO2, cells from the bottom chamber were resuspended and counted using a FACS Scan over 20 seconds. All assays were performed in triplicate and counts were repeated twice for each well. For tyrosine kinase inhibitor treatment, 1x107 mast cells were pretreated for 1.5 hours at 37degreesC in complete medium (OPTI MEM, 10% foetal calf serum (FCS), 1% antibiotics and 2-mercaptoethanol 5x10-5 M, 10 ng/ml rIL3) either with 1 microM of inhibitor or an equivalent volume of DMSO.
###end p 65
###begin title 66
Molecular modelling
###end title 66
###begin p 67
###xml 228 232 228 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Wang1">[36]</xref>
X-ray coordinates of the STI571/ABL (1IEP.pdb) and STI571/KIT (1T46.pdb) X-ray structures were taken from the Protein Databank and used in combination with our in-house docking program, ParaDocks, and the X-Score of Wang et al. [36] to dock masitinib into ABL and KIT. Figures were prepared with PyMOL version 1.00 (DeLano Scientific).
###end p 67
###begin title 68
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
In vivo assays with Ba/F3 Delta27 tumour model
###end title 68
###begin p 69
###xml 171 181 163 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ad libitum</italic>
###xml 466 470 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007258-Circulaire1">[37]</xref>
###xml 854 855 830 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 907 908 883 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 918 919 894 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1074 1075 1050 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 18 22 <span type="species:ncbi:10090">mice</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 767 773 <span type="species:ncbi:9913">bovine</span>
###xml 959 963 <span type="species:ncbi:10090">Mice</span>
###xml 1146 1150 <span type="species:ncbi:10090">mice</span>
Female MBRI Nu/Nu mice (7 weeks old) (Janvier, France) were housed under specific pathogen-free conditions at 20+/-1degreesC with a 12 hours light/12 hours dark cycle and ad libitum access to food and filtered water. The mice were allowed to acclimatise to the study conditions for 10 to 20 days prior to experiments. All animal experiments were performed according to Centre national de la recherche scientifique (CNRS) ethical guidelines of animal experimentation [37]. The animal care unit SCEA (Institut Gustave Roussy, Villejuif, France) is authorised by the French Ministries of Agriculture and Research (Agreement Ndegrees C94-116). The Delta27-expressing Ba/F3 cells were grown in RPMI 1640 medium supplemented with glutamax-1 (Gibco BRL, USA) and 10% foetal bovine serum (Gibco BRL, USA) at 37degreesC in a humidified atmosphere containing 5% CO2. The cells were centrifuged and resuspended at 5x106 or 7.5x106 cells/ml in phosphate-buffered saline. Mice were treated with 5 Gy of gamma radiation and after 24 hours they were injected in the right flank with 1.5x106 Delta27 Ba/F3 cells. When tumour growth had reached the desired size, mice were allocated into treatment groups ensuring that there was no statistical difference between each group's mean body weight and tumour volume. For all animals, body weight was measured on the day of injection and every 5 days thereafter, with the tumour's size measured via callipers every 5 days during the treatment period for estimation of tumour volume. During the predose period and for 2 weeks post-treatment, the animals were checked for mortality or signs of morbidity once a day, increasing to twice a day checks during the treatment period.
###end p 69
###begin title 70
Statistical analysis
###end title 70
###begin p 71
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 302 303 302 303 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 324 331 324 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 332 337 <span type="species:ncbi:10090">mouse</span>
Assays for the in vitro effect of masitinib on the activity of protein kinases were performed as three independent experiments (each in duplicate), with results presented using descriptive statistics. Masitinib's effect on tumour growth was expressed in terms of estimated tumour volume = [lengthxwidth2]/2. Survival in the in vivo mouse studies was assessed by Kaplan-Meier analysis using GraphPad Prism (GraphPad Software, Inc. USA) with comparison of survival curves performed by the logrank Mantel-Cox test. The appropriate Wilcoxon or Kruskall-Wallis tests were used for group comparison of tumour volumes and BMMC migration.
###end p 71
###begin title 72
Supporting Information
###end title 72
###begin p 73
Supplemental Methods
###end p 73
###begin p 74
(0.06 MB DOC)
###end p 74
###begin p 75
Click here for additional data file.
###end p 75
###begin p 76
Effect of imatinib on selected recombinant protein kinases.
###end p 76
###begin p 77
(0.04 MB DOC)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
The authors would like to thank Dr. Francois Bellamy for his helpful review of the manuscript and discussion of the genotoxicity data and the Biometry Department of AB Science for performing statistical analyses.
###end p 79
###begin title 80
References
###end title 80
###begin article-title 81
Signaling by Kit protein-tyrosine kinase - the stem cell factor receptor.
###end article-title 81
###begin article-title 82
Stem cell factor and hematopoiesis.
###end article-title 82
###begin article-title 83
Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.
###end article-title 83
###begin article-title 84
Kit mutations in cancer and their treatment with protein kinase inhibitors.
###end article-title 84
###begin article-title 85
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit.
###end article-title 85
###begin article-title 86
Recent advances in the understanding of mastocytosis: the role of KIT mutations.
###end article-title 86
###begin article-title 87
Role of tyrosine kinase inhibitors in cancer therapy.
###end article-title 87
###begin article-title 88
Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
###end article-title 88
###begin article-title 89
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
###end article-title 89
###begin article-title 90
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
###end article-title 90
###begin article-title 91
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
###end article-title 91
###begin article-title 92
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumours.
###end article-title 92
###begin article-title 93
###xml 27 32 <span type="species:ncbi:9606">human</span>
The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.
###end article-title 93
###begin article-title 94
Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.
###end article-title 94
###begin article-title 95
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
###end article-title 95
###begin article-title 96
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
###end article-title 96
###begin article-title 97
Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumourigenicity of factor-dependent hematopoietic cell lines.
###end article-title 97
###begin article-title 98
The c-kit receptor ligand functions as a mast cell chemoattractant.
###end article-title 98
###begin article-title 99
Signal transduction by several KIT juxtamembrane domain mutations.
###end article-title 99
###begin article-title 100
###xml 41 47 <span type="species:ncbi:10090">murine</span>
Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.
###end article-title 100
###begin article-title 101
FLT3 mutations: biology and treatment.
###end article-title 101
###begin article-title 102
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
###end article-title 102
###begin article-title 103
Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.
###end article-title 103
###begin article-title 104
BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis.
###end article-title 104
###begin article-title 105
In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
###end article-title 105
###begin article-title 106
Protein kinase inhibitors.
###end article-title 106
###begin article-title 107
Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.
###end article-title 107
###begin article-title 108
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
###end article-title 108
###begin article-title 109
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
###end article-title 109
###begin article-title 110
Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors.
###end article-title 110
###begin article-title 111
Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.
###end article-title 111
###begin article-title 112
###xml 43 48 <span type="species:ncbi:9606">human</span>
Autocrine regulation of cord blood-derived human mast cell activation by IL-10.
###end article-title 112
###begin article-title 113
###xml 145 150 <span type="species:ncbi:10090">mouse</span>
IgE mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells.
###end article-title 113
###begin article-title 114
Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.
###end article-title 114
###begin article-title 115
Comparative evaluation of 11 scoring functions for molecular docking.
###end article-title 115
###begin p 116
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: This study was financially supported by AB Science, S.A., Paris, France. AB Science is the proprietary holder of masitinib. Masitinib is under clinical development by AB Science. P.D., S.L., M.C., L.G., M.H., N.C., B.H., A.L., C.A., P.S.L., C.D.M. and A.M. are employees of the study sponsor, AB Science. M.C., M.A. and O.H. are scientific advisors to the study sponsor, AB Science. P.D., M.C., L.G., M.H., A.L., A.M. and O.H. are shareholders of the study sponsor, AB Science. M.C., A.L. and A.M. are applicants on numerous patents pertaining to masitinib.
###end p 116
###begin p 117
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in part by funds from: INSERM (Institut National de la Sante et de la Recherche Medicale); la Ligue Nationale Contre le Cancer "equipe labellisee (P.D.)"; and the "Agence Nationale pour la Recherche", RIB project, France. Financial support for these studies was also provided by AB Science S.A. The sponsor was involved in the study design, data collection, analysis and interpretation, manuscript preparation and in the decision to submit the manuscript.
###end p 117

